AVTX · NASDAQ
Avalo Therapeutics (AVTX) Stock Price & Fundamentals
Avalo Therapeutics (AVTX) closed at $554.23 on Oct 9, 2026, down 0.67% from the previous close of $557.98.
Share price, past year
1Y +50.45%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $554.23 |
| Sep 30, 2026 | $541.73 |
| Aug 31, 2026 | $489.84 |
| Jul 31, 2026 | $476.57 |
| Jun 30, 2026 | $419.53 |
| May 29, 2026 | $401.28 |
| Apr 30, 2026 | $384.32 |
| Mar 31, 2026 | $390.28 |
| Feb 27, 2026 | $408.68 |
| Jan 30, 2026 | $420.46 |
| Dec 31, 2025 | $388.04 |
| Nov 28, 2025 | $358.61 |
| Oct 31, 2025 | $346.47 |
Key statistics
- Market cap
- $29.32B
- P/E (TTM)
- —
- EPS (TTM)
- −$4.48
- Revenue (TTM)
- —
- Net income (TTM)
- −$100.33M
- Shares outstanding
- 52.9M
- Dividend yield
- —
- 52-week range
- $338.91 – $557.98
Avalo Therapeutics's market cap is $29.32B, based on a share price of $554.23 and 52.9M shares outstanding as of Jun 30, 2026.
Financials
Avalo Therapeutics reported revenue of $59.00K for fiscal 2025, down 86.62% from fiscal 2024.
Avalo Therapeutics reported a net loss of $78.26M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $59.00K | −86.6% | −$78.26M | −132,642.4% | −$5.84 | — |
| FY2024ended Dec 31, 2024 | $441.00K | −77.1% | −$35.13M | −7,965.8% | −$20.91 | — |
| FY2023ended Dec 31, 2023 | $1.92M | −89.3% | −$31.54M | −1,639.5% | −$113.58 | — |
| FY2022ended Dec 31, 2022 | $18.05M | +234.4% | −$41.66M | −230.8% | −$1,063.00 | −$26.85M |
| FY2021ended Dec 31, 2021 | $5.40M | −19.4% | −$84.38M | −1,563.1% | — | −$71.01M |
| FY2020ended Dec 31, 2020 | $6.70M | −0.8% | −$63.50M | −947.9% | — | −$40.60M |
| FY2019ended Dec 31, 2019 | $6.75M | −4.0% | −$16.07M | −238.1% | — | −$19.40M |
| FY2018ended Dec 31, 2018 | $7.03M | −74.7% | −$40.05M | −569.9% | −$285.71 | −$3.69M |
| FY2017ended Dec 31, 2017 | $27.81M | +2,312.3% | $11.87M | 42.7% | $100.00 | $12.56M |
| FY2016ended Dec 31, 2016 | $1.15M | — | −$16.47M | −1,428.6% | −$445.24 | −$14.61M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$30.63M | −$2.19 |
| Q4 FY2024ended Dec 31, 2024 | $192.00K | −$35.34M | $137.13 |
| Q3 FY2024ended Sep 30, 2024 | $249.00K | $23.04M | −$2.83 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
| Q1 FY2024ended Mar 31, 2024 | $0.00 | — | — |
| Q4 FY2023ended Dec 31, 2023 | $570.00K | — | — |
| Q3 FY2023ended Sep 30, 2023 | $236.00K | — | — |
| Q2 FY2023ended Jun 30, 2023 | $643.00K | — | — |
Company profile
- Name
- Avalo Therapeutics, Inc.
- Ticker
- AVTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001534120
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jun 23, 2026
- Jun 16, 2026
- Jun 12, 2026
- Jun 8, 2026
- May 13, 2026
- May 13, 2026
Frequently asked questions
What is Avalo Therapeutics's stock price?
Avalo Therapeutics (AVTX) closed at $554.23 on Oct 9, 2026, down 0.67% from the previous close of $557.98.
What is Avalo Therapeutics's market cap?
Avalo Therapeutics's market cap is $29.32B, based on a share price of $554.23 and 52.9M shares outstanding as of Jun 30, 2026.
How much revenue does Avalo Therapeutics make?
Avalo Therapeutics reported revenue of $59.00K for fiscal 2025, down 86.62% from fiscal 2024.
Does Avalo Therapeutics pay a dividend?
Avalo Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Avalo Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures